Molecular basis of anthracycline-induced cardiotoxicity

Heart and Metabolism

Volumn , Issue 35, 2007, Pages

  Vander Heide, Richard S ^a,b   L'Ecuyer, Thomas J ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b John D Dingell Medical Center   (United States)

Author keywords

Anthracycline; Apoptosis; Cardiac muscle; Cardiotoxicity; Mechanism; Oxidative stress

Indexed keywords

ANTHRACYCLINE; ANTIOXIDANT; CATALASE; FREE RADICAL; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; SUPEROXIDE DISMUTASE; THIOREDOXIN;

AEROBIC METABOLISM; ANTIOXIDANT ACTIVITY; APOPTOSIS; CARDIOTOXICITY; DNA DAMAGE; GLYCOLYSIS; HEART FAILURE; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 34548635566     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-314.
2. Von Huff DD, RozencweigM, Layar M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med. 1977;62:200-208.
3. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191-196.
4. L'Ecuyer T, Allebban Z, Thomas R, Vander Heide RS. Glutathione-S- transferase overexpression protects against anthracycline-induced H9C2 cell death. Am J Physiol Heart Circ Physiol. 2004;286:H2057-H2064.
5. Doroshow JH, Locker GY, Meyers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest. 1980;65:128-135.
6. DeAtley SM, Adsenov MY, Adsenova MV, et al. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett. 1999;136:41-46.
7. Dorr RT, Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Eur J Cancer. 1996;32A:S21-S25.
8. Li T, Danielson I, Bello-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res. 2000;46:523-530.
9. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem. 1996;271:12610-12616.
10. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest. 1996;98:1253-1260.
11. Shioji K, Kishimoto C, Nakamura H, et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation. 2002;106:1403-1409.
12. Gianni L, Zweier J, Levy A, Meyers CE. Characterization of the cycle of iron-mediated electron transfer from doxorubicin to molecular oxygen. J Biol Chem. 1985;259:6056-6058.
13. Olson R, Mushlin P. Doxorubicin cardiotoxicity: analysis of prevailing hypothesis. FASEB J. 1990;4:3076-3086.
14. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1998;319:745-752.
15. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117-127.
16. Van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. The Cochrane Database of Systematic Reviews. The Cochrane Collaboration; issue 1, article No. CD 003917. Doi:10:1002/14651858.CD003917.pub2.Oxford: Oxford Update Software 2005.
17. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother. 1994;28:1063-1072.
18. Williams GA, Johnson JR, Burke G. FDA oncology drugs advisory committee review of Zinecard (dexrazoxane, ADR-529, ICRF-187). Rockville, MD: Center for Drug Evaluation and Research, 1992:1-13.
19. Curran CF, Narang PK, Reynolds RD. Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat Rev. 1991;18:241-252.
20. Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert JM. Structure of the doxorubicin-cardiolipin complex role in mitochondrial toxicity. Biophys Chem. 1990;35:247-257.
21. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 2006;41:389-405.
22. Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br J Pharmacol. 2002;135:581-588.
23. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165-167.
24. You H, Kim G, Kim Y, et al. Increased 8-hydroxyguanine formation and endonuclease activity for its repair in ischemic-reperfused hearts of rats. J Mol Cell Cardiol. 2000;32:1053-1059.
25. Golubnitschaja O, Moenkemann H, Kim K, Mozaffari MS. DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14-3-3sigman in taurine-deficient cardiomyocytes. Biochem Pharmacol. 2003;66:511-517.
26. Cutts SM, Parsons PG, Sturm RA, Phillips DR. Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J Biol Chem. 1996;271:5422-5429.
27. Cui H, Schroering A, Diwg HF. p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol Cancer Ther. 2002;1:679-686.
28. Fujikawa K, Kamiya H, Yakushiji H, Fujii Y, Nakabeppu Y, Kasai H. The oxidized forms of dATP are substrates for the human MutT homologue, the hMTH1 protein. J Biol Chem. 1999;274:18201-18205.
29. Takao M, Zhang QM, Yonei S, Yasui A. Differential subcellular localization of human MutY homolog (hMYH) and the functional activity of adenine:8-oxoguanine DNA glycosylase. Nucleic Acids Res. 1999;27:3638-3644.
30. L'Ecuyer T, Sanjeev S, Thomas R, ea. DNA damage is an early event in doxorubicin-induced cardiomyocyte death. Am J Physiol Heart Circ Physiol. 2006; 291:H1273-H1280